Conference Coverage

HPV-Mediated Head, Neck Cancers Predicted to Rise for Decades


 

The good news is that HPV-positivity is associated with improved survival in oropharynx cancer, he said. He highlighted a 2019 study that said radiotherapy and cisplatin improve survival in HPV-positive oropharynx cancer patients. “This has become the de-facto standard of care for locally advanced, low-risk HPV-positive oropharynx cancer,” he said.

Califano reported no relevant disclosures.

Pages

Recommended Reading

Could being active reduce cancer death risk from alcohol?
Federal Practitioner
OK to treat many cancer patients despite pandemic, says ESMO
Federal Practitioner
Hepatitis screening now for all patients with cancer on therapy
Federal Practitioner
Artificial intelligence matches cancer genotypes to patient phenotypes
Federal Practitioner
COVID-19 impact: Less chemo, immune checkpoint inhibitors, and steroids
Federal Practitioner
Aspirin may accelerate cancer progression in older adults
Federal Practitioner
Immunotherapy should not be withheld because of sex, age, or PS
Federal Practitioner
First Evaluation and Summary of The Veterans on Anticancer Medications in Rural and Community Settings Support (VA CARES) Program: Pharmacist-Driven Medication Management for Veterans Receiving Oral Antineoplastic Therapies Through the MISSION/ CHOICE Act
Federal Practitioner
The Importance of Adjuvant Treatment and Primary Anatomical Site in Head and Neck Basaloid Squamous Cell Carcinoma Survival: An Analysis of the National Cancer Database
Federal Practitioner
COVID-19 prompts ‘democratization’ of cancer trials
Federal Practitioner